CAS:145525-41-3Mitiglinide Calcium

您的位置 : 首页 / Membrane Transporter/Ion Channel / Potassium Channel / Mitiglinide Calcium

Mitiglinide Calcium 米格列奈钙 Cat No. FB01625Cas No. 145525-41-3

Synonyms: KAD 1229;S 21403

Mitiglinide calcium is a blood glucose-lowering drugs, stimulating insulin secretion by closing the ATP-sensitive K+ channels in pancreatic beta-cells.

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 1.4950 mL
- 7.4752 mL
- 14.9505 mL
- 5 mM
- 0.2990 mL
- 1.4950 mL
- 2.9901 mL
- 10 mM
- 0.1495 mL
- 0.7475 mL
- 1.4950 mL
计算器摩尔计算器总药量计算器工作液计算器

技术信息

CAS号

145525-41-3

储存条件

粉末: -20°C 3 年

液体: -80°C 12 月

分子式

C38H48CaN2O6

运输

蓝冰

分子量

668.88

别名

KAD 1229;S 21403

溶解度

DMSO	Insoluble
Water	Insoluble
Ethanol	2.0 mg/mL (3.0 mM)

动物实验配方

靶点数据

生物活性

描述Mitiglinide Calcium is a drug for the treatment of type 2 diabetes; it is a highly selective KATP channel antagonist. Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (KATP) channels in pancreatic beta-cells, and its early insulin release and short duration of action would be effective in improving postprandial hyperglycemia. Mitiglinide shows a higher selectivity for the beta-cell type of SUR1/Kir6.2 than the cardiac and smooth muscle types of K(ATP) channels in comparison with glibenclamide and glimepiride. Insulinotropic effect of mitiglinide is more potent than that of nateglinide, and mitiglinide surpassed in controlling postprandial hyperglycemia in normal and diabetic animals. In clinical trials, treatment with mitiglinide provided lasting improvement of postprandial hyperglycemia in Type 2 diabetic patients and decreased the fasting plasma glucose levels and HbA(1C) values^[3]. Mitiglinide induces vasorelaxation via activation of Kv channels and SERCA (sarcoplasmic/endoplasmic reticulum Ca2+-ATPase) pump. However, the vasorelaxant effects of mitiglinide did not involve other K+ channels, Ca2+ channels, PKA/PKG signaling pathways, or the endothelium^[4].